首页> 外文期刊>Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association >Parathyroid hormone-independent osteoclastic resorptive bone disease: a new variant of adynamic bone disease in haemodialysis patients.
【24h】

Parathyroid hormone-independent osteoclastic resorptive bone disease: a new variant of adynamic bone disease in haemodialysis patients.

机译:不依赖甲状旁腺激素的破骨细胞吸收性骨病:血液透析患者中​​无动力性骨病的新变种。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Osteitis fibrosa cystica (OFC) caused by secondary hyperparathyroidism is the pre-eminent form of uraemic osteodystrophy. In recent years, however, new bone abnormalities have been described. Among them adynamic bone disease (ABD) has become a focus of growing interest. Marked suppression of dynamic bone measurements with normal or near-normal static bone-forming parameters are the hallmarks of this disorder. Depressed parathyroid hormone (PTH) levels, frequently evident in this entity, have been linked causally with low bone turnover. METHODS: We reviewed bone biopsy specimens from 96 patients with end-stage renal disease undergoing chronic haemodialysis. RESULTS: We found OFC in 50% of our patients, 20% had mixed bone disease, 24% showed bone morphology of ABD and a minority (6%) had osteomalacia, mostly due to aluminium accumulation. In the patients that were affected by ABD there was a distinct subgroup with bone morphology featuring a striking increase in osteoclast number and osteoclast surface, whereas the osteoid volume, osteoid thickness, osteoblast surface, tetracycline uptake and bone formation rates were diminished as in ordinary ABD. Similarly the PTH levels in this subgroup were low or undetectable. CONCLUSION: We describe patients undergoing chronic haemodialysis with static and dynamic bone forming parameters, indistinguishable from that of ABD, but differing from the classic ABD by the presence of increased osteoclastic bone resorption. The suppressed PTH levels in this subgroup suggests that factors other than PTH activate osteoclasts in some patients on chronic haemodialysis. Uraemic cytokines and/or toxic metabolites, including beta-microglobulin, may be involved in this disorder. The precise nature of this bone abnormality remains to be defined by further studies.
机译:背景:继发性甲状旁腺功能亢进引起的纤维性膀胱炎(OFC)是尿毒症骨营养不良的主要表现形式。然而,近年来,已经描述了新的骨骼异常。其中,无动力性骨病(ABD)已成为人们日益关注的焦点。用正常或接近正常的静态骨形成参数显着抑制动态骨测量是该疾病的标志。甲状旁腺激素(PTH)水平低下(通常在该个体中很明显)与低骨转换率有因果关系。方法:我们回顾了96例接受慢性血液透析的终末期肾脏疾病患者的骨活检标本。结果:我们发现,在50%的患者中,OFC,20%的患者患有混合性骨病,24%的患者表现出ABD的骨形态,而少数(6%)的患者则患有骨软化症,这主要是由于铝的积累。在患有ABD的患者中,有一个明显的骨形态亚组,其破骨细胞数量和破骨细胞表面显着增加,而与普通ABD相比,类骨质的体积,类骨质厚度,成骨细胞表面,四环素的摄取和骨形成率均降低了。同样,该亚组中的PTH水平较低或无法检测。结论:我们描述了具有静态和动态骨形成参数的慢性血液透析患者,该参数与ABD并无区别,但由于破骨细胞骨吸收增加而与经典ABD不同。在该亚组中,PTH水平受到抑制,表明在某些进行慢性血液透析的患者中,除PTH以外的其他因子可激活破骨细胞。尿毒症细胞因子和/或有毒代谢产物(包括β-微球蛋白)可能与这种疾病有关。这种骨异常的确切性质仍有待进一步研究确定。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号